TABLE 1.
Demographics, clinical characteristics, and outcomes of patients at diagnosis of SARS-CoV-2a
| Patient characteristics (n = 15) | Value |
|---|---|
| Age (median [IQR] [yrs]) | 67 (51–79) |
| No. of males (%) | 12 (80) |
| Comorbidities (no. [%]) | |
| Hypertension | 10 (66.7) |
| Diabetes | 7 (46.7) |
| Dyslipidemia | 8 (53.3) |
| Respiratory disease | 5 (33.3) |
| COPD | 3 (20) |
| Obstructive sleep apnea | 1 (6.7) |
| Interstitial lung disease | 2 (13.3) |
| Lung cancer | 1 (6.7) |
| Ischemic heart disease | 1 (6.7) |
| Cancer | 6 (40) |
| Chronic liver disease | 4 (26.7) |
| HIV | 2 (13.3) |
| Myelodysplastic syndrome | 1 (6.7) |
| Radiologic findings (no. [%]) | |
| Pneumonia | 6 (40) |
| Bilateral opacities | 6 (40) |
| Laboratory findings (median [IQR]) | |
| Lymphocyte count (mm3) | 950 (400–1,300) |
| Platelet count (mm3) | 182,500 (116,250–316,250) |
| Ferritin (mg/dl) | 2,032 (466–2,647) |
| D-dimer (mg/dl) | 553 (282–1,642) |
| CRP (mg/dl_) | 4.15 (1.9–9.3) |
| Treatment | |
| Systemic corticosteroids (no. [%]) | 6 (40) |
| Remdesivir (no. [%]) | 3 (20) |
| Tocilizumab (no. [%]) | 1 (6.7) |
| Oxygen therapy (no. [%]) | 7 (46.7) |
| Nasal cannula (no. [%]) | 7 (46.7) |
| High-flow nasal cannula (no. [%]) | 3 (6.7) |
| Invasive mechanical ventilation (no. [%]) | 2 (13.3) |
| No. of days on invasive ventilation (median [IQR]) | 7.5 (3) |
| Clinical outcomes (no. [%]) | |
| ICU admissions | 2 (13.3) |
| Discharge from hospital | 10 (66.7) |
| Death | 5 (33.3) |
| Death related to COVID-19 | 4 (26.7) |
a
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; HIV, human immunodeficiency virus; CRP, C-reactive protein; ICU, intensive care unit.